Cardiotoxicity of cancer therapeutics: current issues in screening, prevention and therapy

Cardiotoxicity of cancer therapeutics: current issues in screening, prevention and therapy

In the context of modern cancer chemotherapeutics, cancer survivors are living longer and being exposed to potential comorbidities related to non-cancer side effects of such treatments. With close monitoring of cancer patients receiving potentially cardiotoxic medical therapies, oncologists and card...

Full description

Bibliographic Details
Main Authors:	Richard Joseph Sheppard, Jenna eBerger, Igal A Sebag
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-03-01
Series:	Frontiers in Pharmacology
Subjects:	Anthracyclines Echocardiography Heart Failure chemotherapy cardiotoxicity predictors
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00019/full

Similar Items

The effect of anthracyclines in minimal doses on cardiac function of children under chemotherapy
by: Shiva Rahimi Dehgolan, et al.
Published: (2014-07-01)

Anthracycline-Induced Cardiotoxicity
by: Jennifer E. Liu, MD
Published: (2020-03-01)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
by: Hui-Min Hu, et al.
Published: (2018-01-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient specific care
by: Shayan Moazeni, et al.
Published: (2017-05-01)

Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
by: Francesco Venturelli, et al.
Published: (2018-09-01)

Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
by: Roberto Ramos Barbosa, et al.

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma
by: Emad Moussa, et al.
Published: (2017-03-01)

Examining Cardiotoxicity With HER2 Therapies∗
by: Neelima Denduluri, MD
Published: (2020-06-01)

Risk Factors for Anthracycline-Induced Cardiotoxicity
by: Shuo Qiu, et al.
Published: (2021-09-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

Cardiovascular toxicities from systemic breast cancer therapy
by: Shuang eGuo, et al.
Published: (2014-12-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy
by: Muthiah Vaduganathan, MD, MPH, et al.
Published: (2019-09-01)

High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
by: George E. G. Kluck, et al.
Published: (2020-04-01)

Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review
by: Simona Serini, et al.
Published: (2017-12-01)

Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry)
by: Keiko Inoue, et al.
Published: (2021-03-01)

microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
by: John Henderson, et al.
Published: (2021-08-01)

Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography
by: Rui Zhao, MBBS, et al.
Published: (2020-03-01)

Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

The diagnosis of anthracycline-induced cardiac damage and heart failure
by: Jarosław Dudka, et al.
Published: (2009-05-01)

Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies
by: Aws Sabah Al-Rubaye, et al.
Published: (2019-01-01)

Anthracycline Cardiotoxicity
by: Umberto Campia, MD, MSc, et al.
Published: (2020-06-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity
by: David S. Monahan, et al.
Published: (2021-08-01)

Cardiotoxicity of Anthracyclines
by: Daniela Cardinale, et al.
Published: (2020-03-01)

Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy
by: Mária Lódi, et al.
Published: (2020-12-01)

Subclinical Anthracycline-Induced Cardiotoxicity in the Long - Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis
by: Yu Kang, et al.

Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines
by: Mladosievicova Beata, et al.
Published: (2012-10-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
by: Alessandra Murabito, et al.
Published: (2020-03-01)

Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs
by: Agapios Sachinidis
Published: (2020-04-01)

Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
by: Maria C. Arciniegas Calle, et al.
Published: (2018-10-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Natural Products Counteracting Cardiotoxicity during Cancer Chemotherapy: The Special Case of Doxorubicin, a Comprehensive Review
by: Izabela Koss-Mikołajczyk, et al.
Published: (2021-09-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I
by: Chazova I.Ye., et al.
Published: (2017-09-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I
by: I Ye Chazova, et al.
Published: (2017-12-01)

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
by: Sarju Ganatra, et al.
Published: (2019-01-01)